scholarly journals Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Youlian Zhou ◽  
Haoming Xu ◽  
Hongli Huang ◽  
Yingfei Li ◽  
Huiting Chen ◽  
...  
Keyword(s):  
Fecal Microbiota Transplantation ◽  
Therapeutic Option ◽  
Fecal Microbiota ◽  
Microbial Dysbiosis ◽  
Therapeutic Value ◽  
Effective Therapeutic Option ◽  
Potential Applications ◽  
Fecal Bacteriotherapy ◽  
Inflammatory Bowel ◽  
Irritable Bowel

Intestinal microbial dysbiosis is associated with various intestinal and extraintestinal disorders. Fecal microbiota transplantation (FMT), a type of fecal bacteriotherapy, is considered an effective therapeutic option for recurrent Clostridium difficile infection (rCDI) and also has important value in other intestinal diseases including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). The purpose of this review is to discuss promising therapeutic value in extraintestinal diseases associated with gut microbial dysbiosis, including liver, metabolic, chronic kidney, neuropsychiatric, allergic, autoimmune, and hematological diseases as well as tumors.

Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders

2020 ◽  
Vol 15 (12) ◽  
pp. 1173-1183
Author(s):  
Gianluca Ianiro ◽  
Jonathan P Segal ◽  
Benjamin H Mullish ◽  
Mohammed N Quraishi ◽  
Serena Porcari ◽  
...  
Keyword(s):  
Fecal Microbiota Transplantation ◽  
Multidrug Resistant ◽  
Fecal Microbiota ◽  
Current Evidence ◽  
Resistant Bacteria ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Inflammatory Bowel ◽  
Irritable Bowel

Fecal microbiota transplantation (FMT) is the infusion of feces from a healthy donor into the gut of a recipient to treat a dysbiosis-related disease. FMT has been proven to be a safe and effective treatment for Clostridioides difficile infection, but increasing evidence supports the role of FMT in other gastrointestinal and extraintestinal diseases. The aim of this review is to paint the landscape of current evidence of FMT in different fields of application (including irritable bowel syndrome, inflammatory bowel disease, liver disorders, decolonization of multidrug-resistant bacteria, metabolic disorders and neurological disorders), as well as to discuss the current regulatory scenario of FMT, and hypothesize future directions of FMT.

Fecal microbiota transplantation. Prospects in pediatric practice

2021 ◽  
Vol 19 (3) ◽  
pp. 37-45
Author(s):  
E.S. Pimenova ◽  
◽  
E.M. Mukhametova ◽  
E.Ya. Musaeva ◽  
S.I. Erdes ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clostridium Difficile ◽  
Short Bowel Syndrome ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Pediatric Practice ◽  
Short Bowel ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Irritable Bowel

The aim of this review is to summarize data on the experience of using fecal microbiota transplantation (FMT) as a method of treating intestinal diseases, in particular in pediatric practice. FMT is the process of transferring fecal material from a healthy donor to the recipient’s gastrointestinal tract in order to alter gut microbial composition. To date, the most amount of research has been conducted in the field of treatment for Clostridium difficile infection. The mortality rate among children with this pathology is 1–5%. Randomized clinical trials show a higher efficacy of FMT compared to the use of antibiotics (efficacy rates of 90% and 26%, respectively) in the treatment for C. difficile infection. The effectiveness of FMT as a treatment for other diseases has been discussed. Cases of the successful use of FMT as a treatment for short bowel syndrome in children have been described, and studies on the effectiveness of this technique in patients with irritable bowel syndrome and inflammatory bowel diseases have been conducted. Most studies have been carried out on small samples of patients, and the results vary. The potential of using FMT as a treatment of children with severe bowel diseases is high, which makes it necessary to conduct further research in pediatric practice. Key words: inflammatory bowel disease, Clostridium difficile infection, short bowel syndrome, irritable bowel syndrome, fecal microbiota transplantation

scholarly journals Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives

2020 ◽  
Vol 9 (11) ◽  
pp. 3535
Author(s):  
Marcantonio Gesualdo ◽  
Felice Rizzi ◽  
Silvia Bonetto ◽  
Stefano Rizza ◽  
Federico Cravero ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Fecal Microbiota Transplantation ◽  
Current Knowledge ◽  
Research Area ◽  
Fecal Microbiota ◽  
Pancreatic Diseases ◽  
Rheumatologic Diseases ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
The One

Gut microbiota represent an interesting worldwide research area. Several studies confirm that microbiota has a key role in human diseases, both intestinal (such as inflammatory bowel disease, celiac disease, intestinal infectious diseases, irritable bowel syndrome) and extra intestinal disorders (such as autism, multiple sclerosis, rheumatologic diseases). Nowadays, it is possible to manipulate microbiota by administering prebiotics, probiotics or synbiotics, through fecal microbiota transplantation in selected cases. In this scenario, pancreatic disorders might be influenced by gut microbiota and this relationship could be an innovative and inspiring field of research. However, data are still scarce and controversial. Microbiota manipulation could represent an important therapeutic strategy in the pancreatic diseases, in addition to standard therapies. In this review, we analyze current knowledge about correlation between gut microbiota and pancreatic diseases, by discussing on the one hand existing data and on the other hand future possible perspectives.

scholarly journals Fecal microbiota transplantation in refractory ulcerative colitis – a case report

2019 ◽  
Vol 47 (2) ◽  
pp. 1072-1079 ◽  
Author(s):  
B. D. Moutinho ◽  
J. P. Baima ◽  
F. F. Rigo ◽  
R. Saad-Hossne ◽  
J. Rodrigues ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Fecal Microbiota Transplantation ◽  
Present Report ◽  
Therapeutic Option ◽  
Alternative Therapy ◽  
Fecal Microbiota ◽  
Clinical Activity ◽  
Microbial Composition ◽  
Inflammatory Bowel ◽  
And Function

Studies comparing gut microbiota profiles of inflammatory bowel disease (IBD) patients have shown several changes in microbiota composition, with marked reduction of local biodiversity relative to that of healthy controls. Modulation of the bacterial community is a promising strategy to reduce the proportion of harmful microorganisms and increase the proportion of beneficial bacteria; this is expected to prevent or treat IBD. The exact mechanism of fecal microbiota transplantation (FMT) remains unknown; however, replacing the host microbiota can reestablish gut microbial composition and function in IBD patients. The present report describes an ulcerative colitis patient who underwent FMT. A 17-year-old male with moderate to severe clinical activity, which was refractory to mesalazine, azathioprine, and infliximab, underwent FMT as alternative therapy. The patient exhibited clinical improvement after the procedure; however, the symptoms returned. A second FMT was performed 8 months after the first procedure, but the patient did not improve. In conclusion, despite the FMT failure observed in this patient, the procedure is a promising therapeutic option for IBD patients, and more in-depth studies of this method are needed.

scholarly journals Current status, complications and prospects of fecal microbiota transplantation therapy

2021 ◽  
Vol 5 (1) ◽  
pp. 004-009
Author(s):  
Ohara Tadashi
Keyword(s):  
Fecal Microbiota Transplantation ◽  
Gastrointestinal Diseases ◽  
The United States ◽  
Fecal Microbiota ◽  
Current Status ◽  
Recurrent Clostridium Difficile Infection ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Highly Virulent ◽  
Transplantation Therapy

Currently, the emergence of highly virulent mutants in Europe and the United States has caused refractory recurrent Clostridium difficile infection (RCDI) to be a problem in clinical practice. In 2013, the Netherland group demonstrated breakthrough therapeutic efficacy in fecal microbial transplant (FMT) treatment clinical trials for RCDI, and FMT treatment is rapidly gaining attention. In addition to RCDI, FMT treatment has been attempted in various gastrointestinal diseases such as inflammatory bowel disease, irritable bowel syndrome and chronic constipation, as well as extragastrointestinal diseases. In this review, I would like to describe the current status, complications and prospects of FMT treatment.

scholarly journals Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms

Gut Microbes ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 1-16
Author(s):  
Patrick Denis Browne ◽  
Frederik Cold ◽  
Andreas Munk Petersen ◽  
Sofie Ingdam Halkjær ◽  
Alice Højer Christensen ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Strictly Anaerobic ◽  
Oxygen Sensitive ◽  
Irritable Bowel

scholarly journals Fecal Microbiota Transplant in Two Ulcerative Colitis Pediatric Cases: Gut Microbiota and Clinical Course Correlations

2020 ◽  
Vol 8 (10) ◽  
pp. 1486
Author(s):  
Andrea Quagliariello ◽  
Federica Del Chierico ◽  
Sofia Reddel ◽  
Alessandra Russo ◽  
Andrea Onetti Muda ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Clinical Effects ◽  
Phylogenetic Distance ◽  
Fecal Microbiota Transplant ◽  
Inflammatory Bowel ◽  
Clinical Conditions ◽  
And Control

Fecal microbiota transplantation (FMT) is a promising strategy in the management of inflammatory bowel disease (IBD). The clinical effects of this practice are still largely unknown and unpredictable. In this study, two children affected by mild and moderate ulcerative colitis (UC), were pre- and post-FMT monitored for clinical conditions and gut bacterial ecology. Microbiota profiling relied on receipts’ time-point profiles, donors and control cohorts’ baseline descriptions. After FMT, the improvement of clinical conditions was recorded for both patients. After 12 months, the mild UC patient was in clinical remission, while the moderate UC patient, after 12 weeks, had a clinical worsening. Ecological analyses highlighted an increase in microbiota richness and phylogenetic distance after FMT. This increase was mainly due to Collinsella aerofaciens and Eubacterium biforme, inherited by respective donors. Moreover, a decrease of Proteus and Blautia producta, and the increment of Parabacteroides, Mogibacteriaceae, Bacteroides eggerthi, Bacteroides plebeius, Ruminococcus bromii, and BBacteroidesovatus were associated with remission of the patient’s condition. FMT results in a long-term response in mild UC, while in the moderate form there is probably need for multiple FMT administrations. FMT leads to a decrease in potential pathogens and an increase in microorganisms correlated to remission status.

Irritable bowel syndrome and transplantation of fecal microbiota. Review

2021 ◽  
Author(s):  
G. D. Fadieienko ◽  
O. Y. Gridnyev
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Microbiota Transplantation ◽  
Positive Outcome ◽  
Fecal Microbiota ◽  
Cochrane Library ◽  
Placebo Control ◽  
Global Improvement ◽  
Recurrent Clostridium Difficile Infection ◽  
Significant Difference ◽  
Irritable Bowel

Objective — to perform analysis of the literature data as regards the efficacy of the use of fecal microbiota transplantation (FMT) in patients with the irritable bowel syndrome (IBS). Materials and methods. The systematic review of the literature (PubMed, MEDLINE, Cochrane Library) has been performed to assess the results of investigation on the use of FMT in adult IBS patients. Results. Currently, FMT is a safe and highly successful method of treatment for recurrent Clostridium difficile infection, and possibility to use FMT in the treatment of other diseases is under investigation. The results of FMT treatment of patients with IBS are contradictory. A number of authors outline fairly high FMT efficacy when used for the treatment of patients with IBS, refractory to the standard methods: it varies from 36 % to 70 % with a duration of adequate symptoms’ relief up to 1 year. However, other authors indicate that the positive FMT clinical effect lasted from 8 weeks to 3 months, after which there was a gradual recovery of symptoms. At the same time, the researchers noted that mostly often the positive outcome was reached after FMT from donors with a higher number of streptococci in the feces. Still others point out that there was no sustained, at least 50‑point reduction in the severity of IBS symptoms from baseline. Some authors did not reveal the advantages of FMT over placebo control and even reported about the higher placebo efficacy. After data generalization no significant difference was revealed in the global improvement in IBS symptoms in patients receiving donor FM versus placebo. However, the attention is drawn to the relationship between the results of FMT with methodology. Indeed, several studies have shown that placebo capsules were more effective than capsules containing donor feces, whereas FMT from donor stool delivered by colonoscopy was superior to FMF from autologous stool. This may be due to the excipients, containing in the capsulated FMT. A number of researchers also indicated that the use of a super donor is necessary for successful FMT and that the response to FMT is dose dependent. Conclusions. To resolve the issue of the expediency of using FMT in routine clinical practice in patients with IBS, more qualitative controlled studies, involving large cohorts of IBS patients and long‑term follow‑up, are required.  

Sign in / Sign up

Export Citation Format

Share Document